Mushrooms for Chemo Side Effects: The Evidence by Symptom

Mushrooms & Chemotherapy Side Effects

55% reported nausea improved

A 2024 cross-sectional survey of 1,374 cancer patients taking Reishi mushroom found that 55% reported nausea improved significantly, 52% fatigue, and 51% appetite. It is among the largest patient-reported outcomes datasets on mushrooms and chemo side effects.

Li et al., Integrative Medicine Research, 2024

1,374

cancer patients in the Reishi symptom survey (Li 2024)

12 years

of lentinan clinical data on nausea reduction in China (Zhang 2018)

3 species

with the strongest matched evidence: lentinan (nausea), reishi (fatigue), PSK (immune)

Li et al., Integrative Medicine Research, 2024

In 2024, a team of researchers published one of the largest patient surveys conducted on mushrooms and chemotherapy side effects. They asked 1,374 cancer patients who were taking Reishi mushroom what happened to their symptoms. More than half said nausea improved significantly. More than half said fatigue improved. More than half said appetite improved.^[1] This is an observational survey, not a randomized trial, and the limitations matter. But the scale is unusually large, and it joins a body of evidence that now includes randomized clinical trials, systematic reviews, and 12-year clinical datasets.

The most useful way to read this evidence is by symptom. The species with the strongest data for nausea is not the same species with the strongest data for immune recovery. Lentinan (from Shiitake) has the most specific nausea and GI data, from 12 years of clinical use in China. Reishi has the largest fatigue dataset. PSK (from Turkey Tail) has the strongest evidence for protecting immune cell counts during chemotherapy. This article maps each side effect to the species with the most clinical support. For the broader context of what mushrooms do in cancer treatment, see the complete guide to medicinal mushrooms in cancer treatment.

The Side-Effect-to-Species Map: What Has the Strongest Evidence

Before going deep on each symptom, here is the evidence summary. The strongest evidence for each chemotherapy side effect points to different mushroom species.

This table does not say these species cure or prevent these side effects. It maps where the clinical data is most concentrated. Each section below explains what the studies actually measured and what they found.

Nausea and GI Symptoms: Lentinan Has 12 Years of Clinical Data

The mushroom compound with the most specific clinical evidence for nausea reduction in chemotherapy patients is not from the species you'd expect. It is lentinan, a beta-glucan polysaccharide from Shiitake, available in the West as a supplement but used for decades as an injectable drug approved in Japan and China for cancer treatment.

Zhang and colleagues (2018) reviewed 12 years of lentinan clinical data in China, covering its use in lung cancer patients undergoing platinum-based chemotherapy.^[4] Lentinan reduced the incidence of chemotherapy adverse reactions including nausea, vomiting, and bone marrow suppression. It also improved quality of life scores and immune function markers. The review covers both the clinical results and the regulatory status: lentinan is not a supplement in the Chinese oncology context, it is an approved cancer drug administered intravenously. That distinction matters when evaluating the evidence quality.

The mechanism for nausea reduction is partly immunological. Platinum-based chemotherapy (cisplatin, carboplatin) causes nausea through multiple mechanisms including direct gut toxicity and central nervous system effects via cytokines. Lentinan's immunomodulatory effects reduce the pro-inflammatory cytokine burden that contributes to chemotherapy-induced nausea and vomiting, alongside its direct effects on bone marrow function.

Agaricus blazei Murill provides the strongest randomized controlled trial evidence for nausea in this literature. Ahn and colleagues (2004) enrolled 100 women with cervical, ovarian, or endometrial cancer undergoing chemotherapy and randomly assigned them to Agaricus blazei extract or no supplement alongside their standard chemotherapy.^[3] The Agaricus group showed increased NK cell activity (a measure of immune function) and significantly improved quality of life on multiple measures, including reduced nausea, vomiting, and appetite loss compared to chemotherapy alone.

The Ahn 2004 trial is particularly well-constructed for this query because it enrolled a real chemotherapy patient population, used a validated QoL measure, and had a comparison group. Its n=100 sample is modest but it remains one of the few RCTs with nausea as a specific measured outcome. The 2023 Narayanan systematic review, which synthesized clinical mushroom supplement studies, found that QoL and immune markers improved consistently across species, with no serious adverse events reported.^[2] For more detail on the nausea-specific evidence, the dedicated nausea from chemotherapy article covers the mechanism and trial data in depth.

Fatigue: The 1,374-Patient Reishi Survey and What It Shows

Cancer-related fatigue is the most common and most disabling symptom of chemotherapy, affecting upward of 80% of patients during treatment. It is driven by multiple overlapping mechanisms: bone marrow suppression reducing red blood cell counts, pro-inflammatory cytokines released by both the tumor and the chemotherapy drugs, mitochondrial dysfunction in muscle cells, and hormonal disruption from treatment.

The 2024 Li cross-sectional survey is one of the largest patient-reported outcomes datasets published on mushrooms and cancer fatigue.^[1] Among the 1,374 cancer patients taking Reishi who completed the survey, 52% reported that fatigue improved quite a bit or very much. Nausea and poor appetite also improved in more than half of respondents. Adverse effects were mild: about 9% of respondents reported minor issues such as dry mouth, constipation, or insomnia, and no serious events were attributed to Reishi.

Several limitations apply. This is a cross-sectional survey, not a randomized trial. Patients who chose to take Reishi mushroom may differ systematically from those who did not. There is no comparison group, no placebo, and no way to separate Reishi's contribution from other variables including diet, exercise, or other supplements. Improvement rates in a self-selected population will be higher than what a blinded randomized trial would show.

With those limits stated, the scale of the dataset makes it meaningful. When more than half of 1,374 patients report that a specific symptom improved, that is a signal worth tracking into a randomized trial.

The biological rationale for Reishi specifically targets fatigue's cytokine component. Reishi's triterpenes and polysaccharides modulate pro-inflammatory cytokines including TNF-alpha and interleukin-6. These cytokines are primary drivers of cancer-related fatigue: they signal the hypothalamus to shift resources away from activity and toward immune function, producing the characteristic exhaustion that patients describe. Compounds that reduce the inflammatory cytokine load without suppressing the immune response entirely may address one component of fatigue's mechanism.

Dan and colleagues (2023) reviewed the evidence specifically for gastric, breast, and colorectal cancers and found that mushroom compounds including PSK and lentinan reduced adverse effects including nausea, vomiting, and appetite loss in addition to improving immune markers.^[7] The fatigue-immune connection also appears in the Ahn 2004 RCT: patients in the Agaricus group showed both increased NK cell activity and improved fatigue scores, suggesting that when immune function improves, some components of fatigue may improve alongside it.^[3]

For a deeper look at the fatigue-specific evidence, the chemo-related fatigue article covers the cytokine mechanism and the full Reishi evidence base.

Immune Recovery and White Blood Cell Counts: PSK Has the Strongest Evidence

Chemotherapy-induced neutropenia, the dangerous drop in white blood cells that makes patients vulnerable to infection, is the side effect with the strongest mushroom evidence base, and that evidence points most clearly to PSK from Turkey Tail mushroom.

Steimbach and colleagues (2021) systematically reviewed 16 clinical trials totaling 1,650 patients that used fungal beta-glucans (including lentinan from Shiitake and schizophyllan from Schizophyllum commune) as adjuvants during cancer treatment.^[6] Most of the trials found that giving beta-glucan alongside chemotherapy or radiotherapy reduced the immune suppression those treatments cause and accelerated the recovery of white blood cell counts. The review was careful about the limits: some trials found no statistically significant difference versus control, and the wide methodological variation between studies prevented a pooled quantitative analysis. The authors concluded that beta-glucan administration is safe and well tolerated, while calling for stronger trials to establish efficacy.

Sakamoto and colleagues (2006) conducted a meta-analysis of PSK adjuvant immunochemotherapy in patients with curatively resected colorectal cancer.^[5] PSK combined with chemotherapy improved disease-free and overall survival. The mechanism driving survival benefit was attributed in part to immune restoration: PSK counteracts the immunosuppressive effects that chemotherapy and tumor-derived factors impose on the patient's immune system.

PSK, marketed as KRESTIN in Japan, has been approved as a cancer adjuvant since 1977. It is not a fringe alternative remedy in the Japanese oncology system; it is a regulated pharmaceutical used alongside chemotherapy in gastric, colorectal, and lung cancer treatment. The Western evidence base has not replicated this regulatory status, but the Japanese clinical trial infrastructure has generated decades of data on PSK's immune effects.

The mechanism is specific. PSK works partly by inhibiting tumor-derived TGF-beta, an immunosuppressive signaling protein that tumors release to disable immune surveillance. Chemotherapy drugs also trigger immunosuppressive signaling pathways. PSK counters both, restoring the activity of natural killer cells and T-lymphocytes that chemotherapy depresses. For the biological detail on this mechanism, the trained immunity article covers how beta-glucan compounds interact with innate immune memory.

For the dedicated evidence review on WBC and neutropenia, the neutropenia recovery article covers the PSK mechanism and the full clinical trial data in depth.

What's Approved vs. What's in the Research Stage

For anyone trying to understand where mushroom compounds sit in the medical system, the regulatory picture matters.

Approved for clinical use (injectable, Japan/China):

• Lentinan (from Shiitake): approved cancer drug in Japan and China for use alongside chemotherapy
• PSK/KRESTIN (from Turkey Tail): approved cancer adjuvant in Japan since 1977 for gastric, colorectal, and lung cancer
• Schizophyllan (from Schizophyllum commune): approved in Japan for cervical cancer treatment

Research-stage or supplement-category in Western countries:

• Reishi (Ganoderma lucidum): available as supplement; phase II trials exist but no regulatory approval for cancer treatment in the US or Europe
• Agaricus blazei Murill: supplement category; the Ahn 2004 RCT established clinical interest but no approval
• Turkey Tail whole mushroom or extract: in clinical trials (including a US NIH-funded trial in breast cancer), but not yet approved as adjuvant

The gap between Japan's regulatory acceptance of PSK/lentinan and Western supplement categorization reflects different historical regulatory frameworks and research investment, not a fundamental difference in the evidence's validity. The Japanese RCTs for PSK and lentinan are legitimate clinical trials, published in peer-reviewed journals, and reviewed in Cochrane-level systematic reviews. The Narayanan 2023 systematic review, which limited its scope to clinical studies only, found consistently favorable trends with no serious adverse events across species.^[2]

This regulatory context helps readers understand what "approved" means and what "research-stage" means without implying that the research-stage evidence is worthless. For the broader mechanistic picture of how mushroom polysaccharides produce these effects, the polysaccharides mechanism article covers the anti-tumor and immunomodulatory pathways.

The Safety Counterpoint: Immunostimulation Cuts Both Ways

Most patient-facing resources about mushrooms and chemotherapy leave out the safety consideration that matters most. Mushroom compounds are immunostimulatory. That is the mechanism behind most of their benefits in chemotherapy: they restore immune function that chemotherapy suppresses. But immunostimulation is the opposite of what immunosuppressant drugs are designed to do.

Patients who take immunosuppressant drugs for organ transplant or autoimmune conditions face a specific risk: immunostimulatory supplements could theoretically reduce the efficacy of medications intended to keep their immune system from attacking a transplanted organ or their own tissue. This concern follows directly from the immunostimulatory mechanism these compounds share. The Steimbach 2021 review found beta-glucan adjuvants to be broadly safe and well tolerated in cancer patients, but those trials did not test the interaction with immunosuppressant drugs, so this specific risk remains uncharacterized rather than ruled out.^[6]

The hepatotoxicity risk with long-term or high-dose use of certain species is also documented. Agaricus blazei at high doses over extended periods has been associated with liver enzyme elevation in case reports. Long-term high-dose Reishi extract has similar reported risks. These cases involve doses substantially higher than typical supplement use, but the signal exists and is worth reporting honestly. The Li 2024 survey found that adverse effects were mild in the 1,374-patient cohort, with roughly 9% reporting minor issues and none serious, which is reassuring at typical supplement doses, but the survey was not designed to capture hepatotoxicity specifically.^[1]

The honest framing is this: the evidence for mushroom compounds reducing specific chemotherapy side effects is stronger than most patient-facing resources acknowledge. The safety profile at typical doses is also better than most caution-heavy medical sites suggest. Both statements can be true. And the most important safety step is the one that applies to any supplement during active cancer treatment: disclosing all supplement use to the oncology team, because interactions with specific chemotherapy drugs and patient-specific factors (hepatic function, other medications, transplant status) cannot be generalized.

The Bottom Line

The evidence on mushrooms and chemotherapy side effects is species-specific and symptom-specific. Lentinan (Shiitake) has the most concentrated clinical data on nausea and GI symptom reduction, including 12 years of clinical use as an approved cancer drug in Japan and China. Reishi has one of the largest patient-reported outcomes datasets for fatigue, with 52% of 1,374 patients in the 2024 Li survey reporting significant improvement. PSK (Turkey Tail) has the strongest evidence for immune recovery and WBC protection during chemotherapy, supported by meta-analyses and a 1977 Japan regulatory approval as a cancer adjuvant. A 2023 systematic review of clinical studies found favorable QoL and immune trends across species with no serious adverse events. Safety considerations include the immunostimulatory mechanism that may reduce immunosuppressant drug efficacy, and hepatotoxicity risk at high doses with certain species.

Frequently Asked Questions

What mushrooms help with chemotherapy side effects?

The evidence points to different species for different side effects. Lentinan (Shiitake polysaccharide) has the most specific nausea data, with 12 years of clinical evidence from China (Zhang et al., 2018). Reishi (Ganoderma lucidum) has the largest fatigue dataset, with 52% of 1,374 cancer patients reporting significant fatigue improvement in a 2024 survey. PSK from Turkey Tail has the strongest immune recovery evidence, including a meta-analysis showing reduced immunosuppression in colorectal cancer patients on chemotherapy.

Can medicinal mushrooms reduce chemo nausea?

Clinical evidence suggests some mushroom compounds reduce chemotherapy-induced nausea. Lentinan, an injectable compound from Shiitake approved as a cancer drug in Japan and China, reduced nausea and vomiting in lung cancer patients on platinum-based chemotherapy in a 12-year clinical review (Zhang et al., 2018). Ahn et al. (2004) ran an RCT in 100 gynecological cancer patients showing Agaricus blazei Murill extract reduced nausea and vomiting vs. chemotherapy alone. Reishi's 2024 survey (n=1,374) found 55% of patients reported nausea improved.

Do mushrooms help the immune system recover after chemo?

PSK (from Turkey Tail, sold as KRESTIN in Japan) has the strongest evidence for immune recovery during and after chemotherapy. It works by inhibiting immunosuppressive signaling from tumors and chemotherapy drugs, restoring the activity of natural killer cells and T-lymphocytes. Sakamoto et al. (2006) found improved survival in colorectal cancer patients on PSK adjuvant therapy. Steimbach et al. (2021) systematically reviewed clinical trials of fungal beta-glucans and found reduced myelosuppression (bone marrow toxicity) across multiple species.

Which mushroom is best for cancer patients?

There is no single best mushroom for all cancer patients, because different species have stronger evidence for different side effects. PSK (Turkey Tail) is best-evidenced for immune support during chemotherapy. Reishi has the most patient-reported outcomes data for fatigue. Lentinan (Shiitake) has the most specific nausea and GI data. Narayanan et al. (2023) reviewed clinical studies across species and found favorable effects on quality of life and immune markers without serious adverse events, suggesting the evidence base is positive for multiple species depending on the specific need.

What is the research on mushrooms for chemo side effects?

The clinical research base for mushrooms and chemotherapy side effects is more substantial than most Western patient-facing resources acknowledge. Key evidence: Lentinan and PSK are approved cancer drugs in Japan (approved since 1977 for PSK). Narayanan et al. (2023) systematically reviewed clinical-only studies and found consistent QoL and immune benefits. Steimbach et al. (2021) found reduced treatment toxicity including myelosuppression across beta-glucan trials. The 2024 Li survey of 1,374 Reishi users found improvements in fatigue, nausea, and appetite in more than half of respondents. Evidence quality is moderate; more RCTs in Western populations are needed.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2RTHM-01760·Narayanan, Santhosshi et al. (2023). “Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies..” Current oncology reports.Study breakdown →PubMed →↩
3. 3RTHM-00066·Ahn, W-S et al. (2004). “Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy..” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.Study breakdown →PubMed →↩
4. 4RTHM-00538·Zhang, Yiran et al. (2018). “Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China..” Journal of cancer research and clinical oncology.Study breakdown →PubMed →↩
5. 5RTHM-00200·Sakamoto, Junichi et al. (2006). “Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials..” Cancer immunology.Study breakdown →PubMed →↩
6. 6RTHM-00719·Steimbach, Laiza et al. (2021). “Fungal beta-glucans as adjuvants for treating cancer patients - A systematic review of clinical trials..” Clinical nutrition (Edinburgh.Study breakdown →PubMed →↩
7. 7. Source details for this reference are not yet available.